多模态影像检测肿瘤治疗心脏毒性中的核心脏病学:现有与新兴方法
本文为综述,概述核医学、超声心动图、CT与心脏磁共振等多模态影像在评估肿瘤治疗相关心血管毒性中的作用,指出早期无创检测临床前心脏毒性对改善心血管结局和避免中断救命化疗至关重要,并介绍现有方法与在研方法。
要点
- 早期无创影像检测临床前心脏毒性,可能改善心血管结局并避免停用救命化疗。
- 核医学、超声心动图、CT和心脏磁共振均已用于评估肿瘤治疗的心血管毒性。
- 多种影像方法仍在开发中,本综述概述这些领域的现有与新兴技术。
核心结论
- 早期无创影像检测肿瘤治疗相关心脏毒性对患者照护至关重要,预防临床前心脏毒性可能改善心血管结局并避免停用救命化疗。
研究设计与样本
- 综述,概述核医学、超声心动图、CT和心脏磁共振领域用于评估肿瘤治疗心血管毒性的现有与新兴影像技术。
主要发现
- 过去十年肿瘤治疗复杂性大幅扩展,相关心脏毒性的类型与严重程度也随之扩大。
- 核医学、超声心动图、CT和心脏磁共振均有成熟方法用于评估肿瘤治疗的心血管毒性,且有多种方法在研。
临床怎么用
- 对接受肿瘤治疗的患者,可考虑用多模态无创影像早期识别临床前心脏毒性,以支持心血管结局改善和化疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complexity of cancer therapies has vastly expanded in the last decade, along with type and severity of cardiac toxicities associated with these treatments. Prevention of pre-clinical cardiotoxicity may improve cardiovascular outcomes and circumvent the decision to place life-sustaining chemotherapeutic agents on hold, making the early detection of cancer therapeutic related cardiac toxicity with non-invasive imaging essential to the care of these patients. There are several established methods of cardiac imaging in the areas of nuclear cardiology, echocardiography, computed tomography, and cardiac magnetic resonance imaging that are used to assess for cardiovascular toxicity of cancer treatments, with several methods under development. The following review will provide an overview of current and emerging imaging techniques in these areas.
引用
- Soufer A, Liu C, Henry ML, et al. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. J Nucl Cardiol. 2019. PMID: 30868378. doi:10.1007/s12350-019-01671-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。